Characteristics and outcome of acute heart failure patients according to the severity of peripheral oedema.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 06 2019
Historique:
received: 31 08 2018
revised: 10 01 2019
accepted: 11 03 2019
pubmed: 25 3 2019
medline: 6 2 2020
entrez: 26 3 2019
Statut: ppublish

Résumé

Most trials of patients hospitalized for heart failure focus on breathlessness (alveolar pulmonary oedema) but worsening peripheral oedema is also an important presentation. We investigated the relationship between the severity of peripheral oedema on admission and outcome amongst patients with a primary discharge death or diagnosis of heart failure. We tested the hypothesis that severity of peripheral oedema is associated with length of hospital stay and mortality. Patient variables reported to the National Heart Failure Audit for England & Wales between April 2008 and March 2013 were included in this analysis. Peripheral oedema was classified as 'none', 'mild', 'moderate' or 'severe'. Length of stay, mortality during the index admission and for up to three years after discharge are reported. Of 121,214 patients, peripheral oedema on admission was absent in 24%, mild in 24%, moderate in 33% and severe in 18%. Median length of stay was, respectively, 6, 7, 9 and 12 days (P- < 0.001), index admission mortality was 7%, 8%, 10% and 16% (P- < 0.001) and mortality at a median follow-up of 344 (IQR 94-766) days was 39%, 46%, 52% and 59%. In an adjusted multi-variable Cox model, the hazard ratio for death was 1.51 for severe (P- < 0.001, CI 1.50-1.53), 1.21 for moderate (P- < 0.001, CI 1.20-1.22) and 1.04 (P- < 0.001, CI 1.02-1.05) for mild peripheral oedema compared to patients without peripheral oedema at presentation. Length of hospital stay and mortality during index admission and after discharge increased progressively with increasing severity of peripheral oedema at admission.

Sections du résumé

BACKGROUND
Most trials of patients hospitalized for heart failure focus on breathlessness (alveolar pulmonary oedema) but worsening peripheral oedema is also an important presentation. We investigated the relationship between the severity of peripheral oedema on admission and outcome amongst patients with a primary discharge death or diagnosis of heart failure.
OBJECTIVES
We tested the hypothesis that severity of peripheral oedema is associated with length of hospital stay and mortality.
METHODS
Patient variables reported to the National Heart Failure Audit for England & Wales between April 2008 and March 2013 were included in this analysis. Peripheral oedema was classified as 'none', 'mild', 'moderate' or 'severe'. Length of stay, mortality during the index admission and for up to three years after discharge are reported.
RESULTS
Of 121,214 patients, peripheral oedema on admission was absent in 24%, mild in 24%, moderate in 33% and severe in 18%. Median length of stay was, respectively, 6, 7, 9 and 12 days (P- < 0.001), index admission mortality was 7%, 8%, 10% and 16% (P- < 0.001) and mortality at a median follow-up of 344 (IQR 94-766) days was 39%, 46%, 52% and 59%. In an adjusted multi-variable Cox model, the hazard ratio for death was 1.51 for severe (P- < 0.001, CI 1.50-1.53), 1.21 for moderate (P- < 0.001, CI 1.20-1.22) and 1.04 (P- < 0.001, CI 1.02-1.05) for mild peripheral oedema compared to patients without peripheral oedema at presentation.
CONCLUSION
Length of hospital stay and mortality during index admission and after discharge increased progressively with increasing severity of peripheral oedema at admission.

Identifiants

pubmed: 30905515
pii: S0167-5273(18)34755-7
doi: 10.1016/j.ijcard.2019.03.020
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

40-46

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Ahmad Shoaib (A)

Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University and Royal Stoke Hospital, Stoke-on-Trent, UK; Department of Academic Cardiology, University of Hull, Kingston upon Hull, UK. Electronic address: ahmad.shoaib@keele.ac.uk.

Mamas A Mamas (MA)

Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University and Royal Stoke Hospital, Stoke-on-Trent, UK.

Qazi S Ahmad (QS)

Department of Academic Cardiology, University of Hull, Kingston upon Hull, UK.

Theresa M McDonagh (TM)

Faculty of Life Sciences and Medicine, King's College London, London, UK.

Suzanna M C Hardman (SMC)

Clinical & Academic Department of Cardiovascular Medicine, Whittington Hospital, London, UK.

Muhammad Rashid (M)

Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University and Royal Stoke Hospital, Stoke-on-Trent, UK.

Robert Butler (R)

Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University and Royal Stoke Hospital, Stoke-on-Trent, UK.

Simon Duckett (S)

Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University and Royal Stoke Hospital, Stoke-on-Trent, UK.

Duwarakan Satchithananda (D)

Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University and Royal Stoke Hospital, Stoke-on-Trent, UK.

James Nolan (J)

Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University and Royal Stoke Hospital, Stoke-on-Trent, UK.

Henry J Dargie (HJ)

Department of Cardiology, University of Glasgow, UK.

Andrew L Clark (AL)

Department of Academic Cardiology, University of Hull, Kingston upon Hull, UK.

John G F Cleland (JGF)

Department of Academic Cardiology, University of Hull, Kingston upon Hull, UK; Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow, Glasgow, Scotland, UK; National Heart and Lung Institute, Imperial College, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH